{"transactions":[{"id":1229371,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T16:15:14.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":10925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":10925,"derivative":{"underlying":"Common Stock","underlying_shares":10925},"source":{"system":"sec-edgar","filing":"0001415889-25-006495","document":"form4-03042025_040310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925006495/form4-03042025_040310.xml","form_type":"4"}},{"id":1229370,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T16:15:14.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-006495","document":"form4-03042025_040310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925006495/form4-03042025_040310.xml","form_type":"4"}},{"id":1229369,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:15:14.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":27258,"price":1.99,"value":54243.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":265662,"source":{"system":"sec-edgar","filing":"0001415889-25-006495","document":"form4-03042025_040310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925006495/form4-03042025_040310.xml","form_type":"4"}},{"id":1229368,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:15:14.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":10925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":292920,"source":{"system":"sec-edgar","filing":"0001415889-25-006495","document":"form4-03042025_040310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925006495/form4-03042025_040310.xml","form_type":"4"}},{"id":1229367,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:15:14.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":281995,"source":{"system":"sec-edgar","filing":"0001415889-25-006495","document":"form4-03042025_040310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925006495/form4-03042025_040310.xml","form_type":"4"}},{"id":1285157,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":293500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":293500,"derivative":{"exercise_price":2.4,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":293500},"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285156,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":83900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":83900,"derivative":{"underlying":"Common Stock","underlying_shares":83900},"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285155,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":44250,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285154,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285153,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":11317,"price":2.48,"value":28066.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":231995,"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285152,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":243312,"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1285151,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-04T16:15:14.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":228562,"source":{"system":"sec-edgar","filing":"0001415889-25-002940","document":"form4-02042025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925002940/form4-02042025_040206.xml","form_type":"4"}},{"id":1315200,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:12.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":false,"shares":17380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":35287,"derivative":{"underlying":"Common Stock","underlying_shares":17380},"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315199,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":52667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":52667,"derivative":{"underlying":"Common Stock","underlying_shares":52667},"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315198,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T18:25:12.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":73750,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315197,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:12.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":221062,"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315196,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:12.000Z","date":"2025-01-02","kind":"exercise","planned":false,"acquired":true,"shares":17380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":229976,"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315195,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:12.000Z","date":"2024-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":32937,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":212596,"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1315194,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T18:25:12.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":245533,"source":{"system":"sec-edgar","filing":"0001415889-25-000624","document":"form4-01032025_060109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588925000624/form4-01032025_060109.xml","form_type":"4"}},{"id":1334096,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-12T16:15:07.000Z","date":"2024-12-10","kind":"gift","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":171783,"source":{"system":"sec-edgar","filing":"0001415889-24-029092","document":"form4-12122024_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000141588924029092/form4-12122024_041201.xml","form_type":"4"}},{"id":1597334,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597333,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":10925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":21850,"derivative":{"underlying":"Common Stock","underlying_shares":10925},"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597332,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597331,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":3531,"price":1.24,"value":4378.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":186783,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597330,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-02","kind":"exercise","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":190314,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597329,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3183,"price":1.24,"value":3946.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":177814,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597328,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":10925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":180997,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597327,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":14569,"price":1.24,"value":18065.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":170072,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1597326,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-05T17:04:56.000Z","date":"2024-03-01","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":184641,"source":{"system":"sec-edgar","filing":"0001209191-24-004402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124004402/doc4.xml","form_type":"4"}},{"id":1659190,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":147500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":147500,"derivative":{"underlying":"Common Stock","underlying_shares":147500},"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1659189,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":59000,"derivative":{"underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1659188,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":206500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":206500,"derivative":{"exercise_price":1.2,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":206500},"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1659187,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1659186,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2583,"price":1.2,"value":3099.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":134641,"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1659185,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:31:24.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":137224,"source":{"system":"sec-edgar","filing":"0001209191-24-002840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919124002840/doc4.xml","form_type":"4"}},{"id":1755268,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-25T16:28:41.000Z","date":"2023-10-23","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":5.0767,"value":30460.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":129724,"source":{"system":"sec-edgar","filing":"0001209191-23-053558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123053558/doc4.xml","form_type":"4"}},{"id":1799802,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-22T16:31:53.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":7.3158,"value":43894.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":135724,"source":{"system":"sec-edgar","filing":"0001209191-23-046905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123046905/doc4.xml","form_type":"4"}},{"id":1846666,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-06-22T16:30:05.000Z","date":"2023-06-20","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":10.2771,"value":61662.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $9.84 to $10.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":141724,"source":{"system":"sec-edgar","filing":"0001209191-23-039070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123039070/doc4.xml","form_type":"4"}},{"id":1974603,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-02","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":12500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974602,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":10925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."}],"balance_after":32775,"derivative":{"underlying":"Common Stock","underlying_shares":10925},"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974601,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974600,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":false,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974599,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":16037,"price":12.6342,"value":202614.6654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.43 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":147724,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974598,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":163761,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974597,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":14800,"price":12.3665,"value":183024.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.90 to $12.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":151261,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974596,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":10925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":166061,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974595,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":155136,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":1974594,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-03T20:12:48.000Z","date":"2023-03-01","kind":"exercise","acquired":true,"shares":13750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":105136,"source":{"system":"sec-edgar","filing":"0001209191-23-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123016065/doc4.xml","form_type":"4"}},{"id":2007975,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-17T16:34:15.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":5000,"price":13.0621,"value":65310.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.79 to $13.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":91386,"source":{"system":"sec-edgar","filing":"0001209191-23-010658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123010658/doc4.xml","form_type":"4"}},{"id":2033344,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T17:07:36.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-007023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123007023/doc4.xml","form_type":"4"}},{"id":2033343,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-02-03T17:07:36.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":105000,"derivative":{"exercise_price":16.97,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-23-007023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919123007023/doc4.xml","form_type":"4"}},{"id":2083973,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-16T16:57:26.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":5000,"price":15.8823,"value":79411.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.56 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":96386,"source":{"system":"sec-edgar","filing":"0001209191-22-061695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122061695/doc4.xml","form_type":"4"}},{"id":2134874,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-10-19T16:45:13.000Z","date":"2022-10-17","kind":"sale","acquired":false,"shares":5000,"price":15.9815,"value":79907.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.72 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":101386,"source":{"system":"sec-edgar","filing":"0001209191-22-054073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122054073/doc4.xml","form_type":"4"}},{"id":2294114,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-20T17:06:25.000Z","date":"2022-04-18","kind":"sale","acquired":false,"shares":30000,"price":16.2766,"value":488298.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":106386,"source":{"system":"sec-edgar","filing":"0001209191-22-025032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122025032/doc4.xml","form_type":"4"}},{"id":2335731,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-14T16:53:56.000Z","date":"2022-03-10","kind":"sale","acquired":false,"shares":27165,"price":15.7115,"value":426802.8975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":136386,"source":{"system":"sec-edgar","filing":"0001209191-22-018501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122018501/doc4.xml","form_type":"4"}},{"id":2355308,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-02","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355307,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355306,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":13750,"derivative":{"underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355305,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":43700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."}],"balance_after":43700,"derivative":{"underlying":"Common Stock","underlying_shares":43700},"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355304,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":153100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date."}],"balance_after":153100,"derivative":{"exercise_price":14.94,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":153100},"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355303,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-02","kind":"exercise","acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":163551,"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355302,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":151051,"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2355301,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T18:11:06.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":13750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":101051,"source":{"system":"sec-edgar","filing":"0001209191-22-015829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122015829/doc4.xml","form_type":"4"}},{"id":2402011,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-11T16:22:08.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":383,"price":12.6818,"value":4857.1294,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections."}],"balance_after":87301,"source":{"system":"sec-edgar","filing":"0001209191-22-008860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122008860/doc4.xml","form_type":"4"}},{"id":2414353,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-03T16:49:39.000Z","date":"2022-02-01","kind":"exercise","acquired":false,"shares":1050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vested on February 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vested on February 1, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1050},"source":{"system":"sec-edgar","filing":"0001209191-22-006836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122006836/doc4.xml","form_type":"4"}},{"id":2414352,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-03T16:49:39.000Z","date":"2022-02-01","kind":"exercise","acquired":true,"shares":1050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":87684,"source":{"system":"sec-edgar","filing":"0001209191-22-006836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919122006836/doc4.xml","form_type":"4"}},{"id":2581964,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-02T17:39:28.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":2333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vested on September 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vested on September 1, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2333},"source":{"system":"sec-edgar","filing":"0001209191-21-054530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121054530/doc4.xml","form_type":"4"}},{"id":2581963,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-02T17:39:28.000Z","date":"2021-09-01","kind":"tax_withholding","acquired":false,"shares":1041,"price":17.22,"value":17926.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":86634,"source":{"system":"sec-edgar","filing":"0001209191-21-054530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121054530/doc4.xml","form_type":"4"}},{"id":2581962,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-09-02T17:39:28.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":2333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":87675,"source":{"system":"sec-edgar","filing":"0001209191-21-054530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121054530/doc4.xml","form_type":"4"}},{"id":2686993,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-02T21:45:41.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 1, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-037478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121037478/doc4.xml","form_type":"4"}},{"id":2686992,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-06-02T21:45:41.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":3550,"price":22.3114,"value":79205.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":85342,"source":{"system":"sec-edgar","filing":"0001209191-21-037478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121037478/doc4.xml","form_type":"4"}},{"id":2686991,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-06-02T21:45:41.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":18240,"price":21.5039,"value":392231.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":88892,"source":{"system":"sec-edgar","filing":"0001209191-21-037478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121037478/doc4.xml","form_type":"4"}},{"id":2686990,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":82469,"kind":"person","name":"Monahan Joseph","position":1,"cik":"0001861790","reported_name":"Monahan Joseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-06-02T21:45:41.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":107132,"source":{"system":"sec-edgar","filing":"0001209191-21-037478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861790/000120919121037478/doc4.xml","form_type":"4"}}]}